Skip to content

MONTPHARMA: what changed

BE 1003.738.776NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€41,561
2024 · €68,590-€27,029
Equity
€111,460
2024 · €70,731+€40,728
Cash
€120,584
2024 · €69,564+€51,020
Balance sheet total
€135,487
2024 · €83,782+€51,705

Largest movements

2024 to 2025
Assets
  • Cash +€51,020

    up €51,020 (+73.3%), from €69,564 to €120,584

    mainly Net result for the year (+€41,561) and Tax, wage and social debts (+€12,307)

  • Receivables within one year +€4,103

    up €4,103 (+42.6%), from €9,623 to €13,726

    of which Other amounts receivable: +€4,727

  • Deferred charges and accrued income -€2,713

    no longer reported in 2025; in 2024 it stood at €2,713

Equity and liabilities
  • Profit (loss) carried forward +€40,728

    up €40,728 (+60.1%), from €67,731 to €108,460

  • Tax, wage and social debts +€12,307

    up €12,307 (+131%), from €9,398 to €21,705

  • Trade debts -€1,780

    down €1,780 (-63.7%), from €2,793 to €1,013

Income statement
  • Gross operating margin -€33,443

    down €33,443 (-37.8%), from €88,530 to €55,087

  • Taxes -€6,603

    down €6,603 (-37.6%), from €17,556 to €10,953

  • Financial charges -€1,786

    down €1,786 (-83.9%), from €2,128 to €342

  • Staff costs +€1,457

    first reported in 2025, at €1,457

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €68,590
Gross operating margin -€33,443
Staff costs -€1,457
Depreciation -€450
Other operating charges -€69
Financial charges +€1,786
Taxes +€6,603
Result 2025 €41,561
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€51,853
Investment €0
Financing -€833
Cash 2024 €69,564
Net result for the year +€41,561
Depreciation +€706
Receivables within one year -€4,103
Deferred charges and accrued income +€2,713
Trade debts -€1,780
Tax, wage and social debts +€12,307
Other debts +€450
Contributions, distributions and other -€833
Cash 2025 €120,584
brings cash intakes cash out
Every line side by side 32 lines
Line Code 2024 2025 Change %
Total assets 20/58 €83,782 €135,487 +€51,705 +61.7%
Fixed assets 21/28 €1,883 €1,177 -€706 -37.5%
Tangible fixed assets 22/27 €1,883 €1,177 -€706 -37.5%
Furniture and vehicles 24 €1,883 €1,177 -€706 -37.5%
Current assets 29/58 €81,899 €134,310 +€52,410 +64.0%
Amounts receivable within one year 40/41 €9,623 €13,726 +€4,103 +42.6%
Trade receivables 40 €9,619 €8,994 -€624 -6.5%
Other amounts receivable 41 €4 €4,731 +€4,727 +118,187%
Cash at bank and in hand 54/58 €69,564 €120,584 +€51,020 +73.3%
Deferred charges and accrued income 490/1 €2,713 - -€2,713
Total equity and liabilities 10/49 €83,782 €135,487 +€51,705 +61.7%
Equity 10/15 €70,731 €111,460 +€40,728 +57.6%
Contributions 10/11 €3,000 €3,000 = 0.0%
Profit (loss) carried forward 14 €67,731 €108,460 +€40,728 +60.1%
Amounts payable 17/49 €13,051 €24,027 +€10,976 +84.1%
Amounts payable within one year 42/48 €13,051 €24,027 +€10,976 +84.1%
Trade debts 44 €2,793 €1,013 -€1,780 -63.7%
Suppliers 440/4 €2,793 €1,013 -€1,780 -63.7%
Taxes, remuneration and social security 45 €9,398 €21,705 +€12,307 +131%
Taxes 450/3 €9,398 €21,705 +€12,307 +131%
Other amounts payable 47/48 €859 €1,309 +€450 +52.4%
Remuneration, social security and pensions 62 - €1,457 +€1,457
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €256 €706 +€450 +176%
Other operating charges 640/8 - €69 +€69
Gross operating margin 9900 €88,530 €55,087 -€33,443 -37.8%
Operating profit (loss) 9901 €88,274 €52,855 -€35,419 -40.1%
Financial charges 65/66B €2,128 €342 -€1,786 -83.9%
Recurring financial charges 65 €2,128 €342 -€1,786 -83.9%
Profit (loss) for the period before taxes 9903 €86,146 €52,514 -€33,633 -39.0%
Income taxes 67/77 €17,556 €10,953 -€6,603 -37.6%
Profit (loss) for the period 9904 €68,590 €41,561 -€27,029 -39.4%
Profit (loss) for the period to be appropriated 9905 €68,590 €41,561 -€27,029 -39.4%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€252,430 to €331,110

Midpoint €285,213 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €111,460
Capitalised earnings €393,400 to €550,760
Indication €252,430 to €331,110

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€111,460
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€111,460

Capitalised earnings

net result for the year (9904)
2025
€41,561
2024
€68,590
Average result
€55,076
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€393,400 / €458,967 / €550,760

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 19 November 2026 via checked.be.